ArticleAMB Express2026
Genomic and spectroscopic analysis for antimicrobial metabolite profiling of Microbacterium testaceum endophyte.
Article in AMB Express, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Wild plants harbor distinct endophytes that produce potent antimicrobial metabolites that can be used to combat life-threatening pathogens. In our study, four bacterial endophytes (LP1, LP2, LP3, LP4) were isolated from the inner tissues of leaves of Pluchea dioscoridis (L.) DC (Barnûf). The antimicrobial activity of the respective extracts (P1, P2, P3, and P4) against standard, multidrug-resistant (MDR), and Candida albicans was determined using the cup agar diffusion method. The P4 extract showed broad-spectrum activity against all tested pathogens and promising antiviral activity. The endophytic bacterium LP4 was microscopically and genomically identified by whole-genome sequencing (WGS) as Microbacterium testaceum (M. testaceum) strain CCASU-2025-88. The extract of endophytic M. testaceum CCASU-2025-88 (LP4) exhibited broad-spectrum antimicrobial activity against standard and multidrug-resistant pathogens as well as antiviral activity against Adenovirus 7, Herpes Simplex Virus 1, and Herpes Simplex Virus 2, and cytotoxic activity with a non-toxic concentration of 7.32 μg/mL, reflecting the promising bioactive properties of LP4 metabolites. Chemical profiling using AntiSMASH and LC-ESI-MS analysis suggested the presence of a compound putatively identified as microansamycin B; however, this assignment remains tentative, since the compound exhibits potent antibacterial activity, and it demonstrates the bioactive potential of M. testaceum metabolites. In conclusion, M. testaceum strain CCASU-2025-88 is a potential source of microansamycin B-like compound based on LC-ESI-MS evidence. This is the first report investigating the production of microansamycin B by a locally isolated endophytic bacterium, M. testaceum CCASU-2025-88. Further studies are recommended to optimize its production and isolation in a pure form.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.